Revolution Medicines logo

Revolution Medicines

RVMD | NASDAQ
Chart Builder DCF Calculator
$166.87
-$5.42 (-3.15%)
At close: Nov 16, 2026, 4:00 PM ET
$167.80
+$0.93 (+0.56%)
After-hours: Nov 16, 2026, 7:57 PM ET
-3.15%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
43.5
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #433/1021 (Top 42%)

Key Statistics

Market Data

Market Cap $36.09B
1D Range
165.95 173.59
52W Range
69.14 221.15

Valuation (TTM)

PE -18.24
PB 15.03
EV/EBITDA -18.64

Valuation (NTM)

Forward PE N/A
Forward PEG -0.38
Price Target $260.00
Loading financial charts...

Profile

Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cance...

Sector Healthcare
Industry Biotechnology
Employees 883
IPO Date Feb 13, 2020
Fiscal Year January - December

Latest News

European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

12 hours ago · globenewswire.com

European Commission Approves Revolution Medicines' RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript

16 hours ago · seekingalpha.com

Revolution Medicines, Inc. (RVMD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High

4 days ago · seekingalpha.com

Revolution Medicines: RASONQUE Is Off To A Strong Start, But Expectations Are High
Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript

6 days ago · seekingalpha.com

Revolution Medicines, Inc. (RVMD) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet

6 days ago · zacks.com

Wall Street Analysts Think Revolution Medicines (RVMD) Could Surge 33.34%: Read This Before Placing a Bet
Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?

9 days ago · fool.com

Revolution Medicines' Pancreatic Cancer Drug Nearly Doubled Survival. Is the High-Flying Stock Still a Buy?
Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It

11 days ago · seekingalpha.com

Revolution Medicines Q3 Earnings: Stellar Company And Drug, But The Market Knows It
RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake

11 days ago · zacks.com

RVMD Q3 Earnings & Sales Beat Estimates on Encouraging Rasonque Uptake
What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What Revolution Medicines (RVMD) Said on Its Q3 Earnings Call
Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Revolution Medicines, Inc. (RVMD) Q3 2026 Earnings Call Transcript

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$1.9
Beat +19.15%
REV
$197.6M
Beat +672.44%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
18
Consensus
Buy
Price Target
$260.00
Upside
+55.81%
Buy (17)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.